NO972526L - Tachykininantagonister - Google Patents

Tachykininantagonister

Info

Publication number
NO972526L
NO972526L NO972526A NO972526A NO972526L NO 972526 L NO972526 L NO 972526L NO 972526 A NO972526 A NO 972526A NO 972526 A NO972526 A NO 972526A NO 972526 L NO972526 L NO 972526L
Authority
NO
Norway
Prior art keywords
phenyl
sulfur
tachykinin antagonists
indol
pyridyl
Prior art date
Application number
NO972526A
Other languages
English (en)
Other versions
NO972526D0 (no
Inventor
Soo Young Ko
Christopher Walpole
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9425085.9A external-priority patent/GB9425085D0/en
Priority claimed from GBGB9426016.3A external-priority patent/GB9426016D0/en
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO972526L publication Critical patent/NO972526L/no
Publication of NO972526D0 publication Critical patent/NO972526D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Forbindelse med formel I, Rj -(CHj)^- I«-C-*I-----CH-C-N-----CH-C-Z-CH-Rj 1^ (b) (C) (I) hvori Rj^ er mono- eller disubstituert fenyl, n er null eller 1, Xj^ er oksygen, svovel eller =NCN, Xj og X3 er oksygen eller svovel, R2 er hydrogen eller metyl, R3 er fenyl, halogen- substituert fenyl, 2-naftyl, lH-indol-3-yl eller 1-metyl- indol-3-yl, Z er -N(CH3)- eller -CHj-, R4 er fenyl, 3,5-bis- (trifluormetyl)fenyl eller pyridyl og R5 er hydrogen, fenyl, 3,5-bis(trifluormetyl)fenyl eller pyridyl, hvorved, når X3 er svovel, er Z -N(CH3)-, og syreaddisjonssalt derav har tachykininantagonistaktivitet og er anvendbare som farma- søytiske midler, f.eks. for behandling av smerte.
NO972526A 1994-12-13 1997-06-03 Tachykininantagonister NO972526D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9425085.9A GB9425085D0 (en) 1994-12-13 1994-12-13 Organic compounds
GBGB9426016.3A GB9426016D0 (en) 1994-12-22 1994-12-22 Organic compounds
PCT/EP1995/004910 WO1996018643A1 (en) 1994-12-13 1995-12-12 Tachykinin antagonists

Publications (2)

Publication Number Publication Date
NO972526L true NO972526L (no) 1997-06-03
NO972526D0 NO972526D0 (no) 1997-06-03

Family

ID=26306161

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972526A NO972526D0 (no) 1994-12-13 1997-06-03 Tachykininantagonister

Country Status (17)

Country Link
EP (1) EP0797583A1 (no)
JP (1) JPH10511935A (no)
AR (1) AR001332A1 (no)
AU (1) AU4343796A (no)
BR (1) BR9509997A (no)
CA (1) CA2204130A1 (no)
CO (1) CO4700289A1 (no)
CZ (1) CZ179097A3 (no)
FI (1) FI971685A (no)
HU (1) HUT77002A (no)
IL (1) IL116323A0 (no)
NO (1) NO972526D0 (no)
PE (1) PE38997A1 (no)
PL (1) PL320217A1 (no)
SK (1) SK74697A3 (no)
TR (1) TR199501568A2 (no)
WO (1) WO1996018643A1 (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
CA2266773A1 (en) * 1996-10-07 1998-04-16 Merck Sharp & Dohme Limited Use of a nk-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
CN1157224C (zh) 1999-02-18 2004-07-14 科研制药株式会社 用作生长激素促分泌剂的新酰胺衍生物
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
KR20080044840A (ko) 2005-07-15 2008-05-21 에이엠알 테크놀로지, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기위한 용도
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
JP5489333B2 (ja) 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション 脂肪酸合成阻害剤を用いた治療の方法
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2336120T3 (pl) 2007-01-10 2014-12-31 Msd Italia Srl Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP2011515343A (ja) 2008-03-03 2011-05-19 タイガー ファーマテック チロシンキナーゼ阻害薬
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
WO2010132442A1 (en) 2009-05-12 2010-11-18 Albany Molecular Reserch, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
EP2429295B1 (en) 2009-05-12 2013-12-25 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
EP2429293B1 (en) 2009-05-12 2014-10-29 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
CA2807307C (en) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
JP2014514321A (ja) 2011-04-21 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション インスリン様増殖因子１受容体阻害剤
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
BR112015012295A8 (pt) 2012-11-28 2023-03-14 Merck Sharp & Dohme Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
MX2015008196A (es) 2012-12-20 2015-09-16 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3706747A4 (en) 2017-11-08 2021-08-04 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
EP3833668A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
JPH05186498A (ja) * 1991-12-27 1993-07-27 Japan Tobacco Inc プロリン誘導体

Also Published As

Publication number Publication date
CA2204130A1 (en) 1996-06-20
JPH10511935A (ja) 1998-11-17
AR001332A1 (es) 1997-10-22
FI971685A0 (fi) 1997-04-18
PE38997A1 (es) 1997-10-02
EP0797583A1 (en) 1997-10-01
IL116323A0 (en) 1996-03-31
NO972526D0 (no) 1997-06-03
FI971685A (fi) 1997-08-13
CZ179097A3 (en) 1997-10-15
AU4343796A (en) 1996-07-03
CO4700289A1 (es) 1998-12-29
HUT77002A (hu) 1998-03-02
SK74697A3 (en) 1997-11-05
WO1996018643A1 (en) 1996-06-20
BR9509997A (pt) 1997-12-30
PL320217A1 (en) 1997-09-15
MX9703957A (es) 1997-09-30
TR199501568A2 (tr) 1996-07-21

Similar Documents

Publication Publication Date Title
NO972526L (no) Tachykininantagonister
DE69133277D1 (de) Chelat-zubereitungen, die oximverbindungen enthalten
EE04310B1 (et) Bensimidasooli ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine
DK1105393T3 (da) Bicykliske piperidin- og piperazinforbindelser med 5-HT6-receptoraffinitet
BG105271A (en) 1h-imidazopyridine derivatives
ATE316961T1 (de) Heterozyclische derivate für die behandlung von herzversagen und andere erkrankungen
NO944919L (no) Fremgangsmåte for å inhibere atrofi av huden eller vagina
DK0463945T3 (da) Chalcon-derivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende derivaterne
ATE283268T1 (de) 2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
ATE173256T1 (de) Azolidindion-derivate und ihre anwendung als antihyperglykämika
HUP0001164A2 (hu) PF1022-ciklodepszipeptid-származékok
DK0719258T3 (da) Cykliske amidderivater til beskyttelse mod ultraviolet stråling
DK0538192T3 (da) Hidtil ukendte 17beta-substituerede aza-androstan-derivater
NO961000L (no) Piperidinderivater, fremgangsmåte for fremstilling derav og medikament og preparat inneholdende slike
NO944926L (no) Fremgangsmåter for å inhibere myeloperoksidaseaktivitet
ATE168105T1 (de) Melamine derivate zur verwendung in der behandlung von krebs
ES2191341T3 (es) Derivados de la 2-fenoxianilina.
JPS6440449A (en) Substituted 2-nitromethaphenylenediamine, manufacture and hair dye composition
DK0778824T3 (da) Carbamoylcarboxylsyreamider
DE59009359D1 (de) Phenylalkylamine und diese enthaltende Fungizide.
ES2105145T3 (es) Nuevos derivados de la pirrolidina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
NO994764L (no) Nye pyridinderivater og farmasöytiske preparater inneholdende disse
DE69706355D1 (de) Alkylendiamin-Derivate als Arzneimittel zur Behandlung von Geschwüren und Hemmung von Helicobacter pylori
TR200003434T2 (tr) Nörojenik iltihabın tedavisi için bir ilacın hazırlanması.
NO992316L (no) Benzensulfonamidderivater og legemidler inneholdende disse